Free Newsletter
Google and Facebook and Twitter, oh my!
Today's the day you pharma marketing folks have been waiting for: The beginning of FDA's two-day public hearing on social-media and online drug promotions. If there's any doubt that inquiring drugmakers want to know, hear this: Some 900 people tried to register for the event, Reuters reports, far outstripping the meeting site's 350-person capacity.
Here's why. Dazed and confused by the array of new online marketing options--and understandably wary of FDA's response to said array--drugmakers have either tiptoed very very carefully or simply abstained. And still, the FDA sent out 14 warning letters on search-engine advertising this past April, prompting lots of pharma firms to just say no to Google promos. Meanwhile, pharma marketers have been wanting to practice their craft on Facebook and Twitter and other up-and-coming online venues, but absent any FDA guidance, why take the risk?
So when FDA announced it would solicit ideas from the industry and other interested parties, a great outcry was heard in the land. Besides the many who signed up to attend the hearings, a whole host of folks volunteered to speak. Including drugmakers such as Sanofi-Aventis, of course, but also vested-interest types like Google.
We'll keep an eye out for the avalanche of ideas that's sure to come out of that Washington-area ballroom. Already, PhRMA pitched the idea of a universal drug safety logo for online ads, clickable to safety info from FDA or someone else. Sanofi regulatory affairs VP Craig Audet suggests that TV-ad rules could serve as a springboard for Internet-ad regulations.
- read the Reuters coverage
- check out the Health Blog post
Related Articles:
Online pharma just got more treacherous
Social media still uncharted for pharma
Is Twitter less troublesome than blogging?
Facebook, Twitter, ect., new marketing tools
BIO: Promoting your biotech through social media
Comments
Its all about creating consumer demand for drugs instead of letting the doctor recommend them.
Dr. Wright
http://www.wrightplacetv.com
Why are they allowed to market to consumers at all?
Post new comment
Paid Research Reports
- The Specialty Pharma Market Outlook: Key players, new company growth models and emerging opportunities
- Investigating Clinical Trial Costs: Comparative analysis of trial cost components in key geographies
- Clinical Trial Recruitment Strategies: Optimizing patient recruitment and retention in late stage clinical trials
- Pipeline Insight: Therapeutic Cancer Vaccines - Prospect of first approval set to reinvigorate interest from major companies
- Stakeholder Opinions: Vaccines in Emerging Markets (Asia) - Opportunities in China, India, South Korea and Taiwan
- Big Pharma Performance Before, During and Beyond the Global Recession






SHARE
WITH: